Zongertinib Patent Expiration
Zongertinib was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Zongertinib Patents
Given below is the list of patents protecting Zongertinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Hernexeos | US11608343 | Substituted Pyrimido[5,4-D]Pyrimidines As Her2 Inhibitors | Jul 21, 2041 | Boehringer Ingelheim |
| Hernexeos | US12171739 | N4-Phenyl-Quinazoline-4-Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases | Nov 15, 2026 | Boehringer Ingelheim |
Zongertinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Zongertinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Boehringer Ingelheim | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | Boehringer Ingelheim | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without Food | Boehringer Ingelheim | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Boehringer Ingelheim | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |